国药控股(01099)：国药一致(000028.SZ)2025年归母净利润11.36亿元 同比增加76.8%

Group 1 - The core point of the article is that China National Pharmaceutical Group (国药控股) has released a performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the year 2025, indicating a mixed financial performance with a slight decline in revenue but a significant increase in net profit [1] Group 2 - The total operating revenue for the year 2025 is reported at 73.416 billion yuan, reflecting a year-on-year decrease of 1.29% [1] - The net profit attributable to shareholders of the listed company is 1.136 billion yuan, which shows a substantial year-on-year increase of 76.8% [1] - The basic earnings per share (EPS) is reported at 2.04 yuan [1]